Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 2
1956 2
1957 2
1962 3
1965 3
1966 4
1967 4
1968 4
1971 3
1973 1
1974 3
1975 4
1976 1
1977 6
1978 3
1979 11
1980 12
1981 7
1982 16
1983 12
1984 14
1985 19
1986 16
1987 21
1988 30
1989 29
1990 28
1991 20
1992 23
1993 18
1994 25
1995 15
1996 23
1997 26
1998 25
1999 27
2000 32
2001 42
2002 32
2003 31
2004 44
2005 51
2006 62
2007 59
2008 51
2009 37
2010 41
2011 58
2012 55
2013 80
2014 82
2015 88
2016 71
2017 79
2018 99
2019 132
2020 138
2021 172
2022 147
2023 106

Text availability

Article attribute

Article type

Publication date

Search Results

2,010 results

Results by year

Filters applied: . Clear all
Page 1
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. Voors AA, et al. Among authors: sakata y. Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228754 Free PMC article. Clinical Trial.
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association.
Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Michael Felker G, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Bozkurt B, et al. Among authors: sakata y. Eur J Heart Fail. 2021 Mar;23(3):352-380. doi: 10.1002/ejhf.2115. Epub 2021 Mar 3. Eur J Heart Fail. 2021. PMID: 33605000 Free article.
Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases.
Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low SK, Okada Y, Terao C, Amariuta T, Gazal S, Kochi Y, Horikoshi M, Suzuki K, Ito K, Koyama S, Ozaki K, Niida S, Sakata Y, Sakata Y, Kohno T, Shiraishi K, Momozawa Y, Hirata M, Matsuda K, Ikeda M, Iwata N, Ikegawa S, Kou I, Tanaka T, Nakagawa H, Suzuki A, Hirota T, Tamari M, Chayama K, Miki D, Mori M, Nagayama S, Daigo Y, Miki Y, Katagiri T, Ogawa O, Obara W, Ito H, Yoshida T, Imoto I, Takahashi T, Tanikawa C, Suzuki T, Sinozaki N, Minami S, Yamaguchi H, Asai S, Takahashi Y, Yamaji K, Takahashi K, Fujioka T, Takata R, Yanai H, Masumoto A, Koretsune Y, Kutsumi H, Higashiyama M, Murayama S, Minegishi N, Suzuki K, Tanno K, Shimizu A, Yamaji T, Iwasaki M, Sawada N, Uemura H, Tanaka K, Naito M, Sasaki M, Wakai K, Tsugane S, Yamamoto M, Yamamoto K, Murakami Y, Nakamura Y, Raychaudhuri S, Inazawa J, Yamauchi T, Kadowaki T, Kubo M, Kamatani Y. Ishigaki K, et al. Among authors: sakata y. Nat Genet. 2020 Jul;52(7):669-679. doi: 10.1038/s41588-020-0640-3. Epub 2020 Jun 8. Nat Genet. 2020. PMID: 32514122 Free PMC article.
JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis.
Nagai T, Inomata T, Kohno T, Sato T, Tada A, Kubo T, Nakamura K, Oyama-Manabe N, Ikeda Y, Fujino T, Asaumi Y, Okumura T, Yano T, Tajiri K, Matsuura H, Baba Y, Sunami H, Tsujinaga S, Ota Y, Ohta-Ogo K, Ishikawa Y, Matama H, Nagano N, Sato K, Yasuda K, Sakata Y, Kuwahara K, Minamino T, Ono M, Anzai T; Japanese Circulation Society Joint Working Group. Nagai T, et al. Among authors: sakata y. Circ J. 2023 Apr 25;87(5):674-754. doi: 10.1253/circj.CJ-22-0696. Epub 2023 Mar 31. Circ J. 2023. PMID: 36908170 Free article. No abstract available.
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y. Hashimoto H, et al. Among authors: sakata y. Lancet Oncol. 2020 Feb;21(2):242-249. doi: 10.1016/S1470-2045(19)30678-3. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838011 Clinical Trial.
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Among authors: sakata y. Chest. 2022 Nov;162(5):1188-1198. doi: 10.1016/j.chest.2022.05.035. Epub 2022 Jun 1. Chest. 2022. PMID: 35661746
Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease.
Koyama S, Ito K, Terao C, Akiyama M, Horikoshi M, Momozawa Y, Matsunaga H, Ieki H, Ozaki K, Onouchi Y, Takahashi A, Nomura S, Morita H, Akazawa H, Kim C, Seo JS, Higasa K, Iwasaki M, Yamaji T, Sawada N, Tsugane S, Koyama T, Ikezaki H, Takashima N, Tanaka K, Arisawa K, Kuriki K, Naito M, Wakai K, Suna S, Sakata Y, Sato H, Hori M, Sakata Y, Matsuda K, Murakami Y, Aburatani H, Kubo M, Matsuda F, Kamatani Y, Komuro I. Koyama S, et al. Among authors: sakata y. Nat Genet. 2020 Nov;52(11):1169-1177. doi: 10.1038/s41588-020-0705-3. Epub 2020 Oct 5. Nat Genet. 2020. PMID: 33020668
JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis　- Digest Version.
Terasaki F, Azuma A, Anzai T, Ishizaka N, Ishida Y, Isobe M, Inomata T, Ishibashi-Ueda H, Eishi Y, Kitakaze M, Kusano K, Sakata Y, Shijubo N, Tsuchida A, Tsutsui H, Nakajima T, Nakatani S, Horii T, Yazaki Y, Yamaguchi E, Yamaguchi T, Ide T, Okamura H, Kato Y, Goya M, Sakakibara M, Soejima K, Nagai T, Nakamura H, Noda T, Hasegawa T, Morita H, Ohe T, Kihara Y, Saito Y, Sugiyama Y, Morimoto SI, Yamashina A; Japanese Circulation Society Joint Working Group. Terasaki F, et al. Among authors: sakata y. Circ J. 2019 Oct 25;83(11):2329-2388. doi: 10.1253/circj.CJ-19-0508. Epub 2019 Oct 9. Circ J. 2019. PMID: 31597819 Free article. No abstract available.
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
2,010 results